Cognito Announces Oversubscribed $105M to Advance Alzheimer’s Therapy
Financing positions company for pivotal study data readout, FDA submission, and 2027 commercialization in Alzheimer’s disease Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive...